Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 228 of 5804
-
New pill aims to shrink tumors in rare nerve disorder
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Trineumin(Code name:PRG-N-01) works to treat Neurofibromatosis Type II(NF2) in adults. It will also learn about the safety and tolerability and toxicity of PRG-N-01. The main questions it aims to answer are: * What dose was determin…
Phase: PHASE1, PHASE2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Cord tissue patches aim to heal stubborn diabetic foot sores
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy of two dehydrated human umbilical cord-based medical devices, also defined as Cellular, Acellular, Matrix-like Products/skin substitutes, plus SOC versus SOC alone in achieving complete closure of hard-to-heal diabetic foot ul…
Phase: NA • Sponsor: StimLabs • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope against superbug pneumonia: Dual-Action antibiotic trial launches
Disease control Not yet recruitingStudy on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New eye injection could mean fewer doctor visits for wet AMD patients
Disease control Not yet recruitingThe goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile. Participants will receive either a periocular injection of AIV007 or intravitrea…
Phase: PHASE2 • Sponsor: AiViva BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic…
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for rare, painful skin disease: experimental drug EPN-701 enters phase 2 trial
Disease control Not yet recruitingCalciphylaxis is a rare but serious condition that leads to painful skin lesions. At present, there is no approved treatment for calciphylaxis. This research study is planned to examine the potential benefits of a new treatment (EPN-701) in patients with calciphylaxis. The presen…
Phase: PHASE2 • Sponsor: Sagar U. Nigwekar, MD, MMSc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Not yet recruitingThis is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and/or refractory myeloma that have failed…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Promising drug cocktail targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis is a phase II trial in patients with locally advanced or metastatic non-small cell lung cancer harboring HER2 gene abnormalities (amplification or overexpression)with a performance status of 0 to1 who are planned to receive first-line treatment or who have falied the first-l…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
One-Time gene fix could free kids from lifelong diet and meds
Disease control Not yet recruitingThis is a single-site Phase 1/2 open-label umbrella clinical trial designed to evaluate the safety, tolerability, and efficacy of a single intravenous dose of LNP.UCD.ABE in 5 pediatric subjects with severe infantile-onset UCDs. This is a master clinical protocol in which subject…
Phase: PHASE1, PHASE2 • Sponsor: Rebecca Ahrens-Nicklas • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Promising drug cocktail aims to save voice boxes in throat cancer patients
Disease control Recruiting nowThis clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma. The primary o…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Scoring balloon aims to crack tough heart plaques for better stent fit
Disease control Not yet recruitingThe purpose of this clinical study is to evaluate the effectiveness and safety of a specialized medical device, the Naviscore scoring balloon, in preparing calcified coronary artery narrowings before the implantation of a drug-eluting stent. During percutaneous coronary intervent…
Phase: NA • Sponsor: University of Mons • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive 'Smart Bombs' target Hard-to-Treat cancers
Disease control Recruiting nowThis is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of \[177Lu\]Lu-A9-0631 and \[225Ac\]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced, unresectable or metastatic solid tumors.
Phase: PHASE1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Smart breathing machines at home could cut hospital visits for COPD patients
Disease control Not yet recruitingThe purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In sta…
Sponsor: Air Liquide Healthcare Spain • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted magnetic pulses aim to lift bipolar depression
Symptom relief Not yet recruitingThis study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood shifts and their related brain circuits in BD. Investi…
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Could dropping aspirin early after stent surgery be safer?
Disease control Not yet recruitingThis is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular ultrasound (IVUS)-guided drug-eluting stent implant…
Phase: PHASE4 • Sponsor: Gyeongsang National University Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Eligible patients will have recurrent or met…
Phase: PHASE2 • Sponsor: Biying Chen • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Weekly shot could help shed pounds in obesity trial
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent chang…
Phase: PHASE2 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New daily pill aims to tame psoriatic arthritis symptoms
Disease control Not yet recruitingRandomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheum…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a gentle surgical approach improve outcomes after deep brain bleeding?
Disease control Not yet recruitingThis observational cohort study evaluates the real-world effectiveness and safety of minimally invasive surgery (MIS) versus standard medical management in adults with spontaneous deep intracerebral hemorrhage. Patients presenting to Tam Anh General Hospital and People's Hospital…
Sponsor: Tam Anh Research Institute • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC